Member Info for Bobbler

https://www.bbc.co.uk/news/world-asia-57624557

A number of posters have suggested GSK might be a potential suitor for Sareum.

Process for proposed COVID-19 treatments(UKRI website)

Once a treatment is submitted, UKRI collates evidence and data on the compound.

The sub-panels consider the briefs and provide advice on the treatments to either:
* UK-CTAP
* COVID-19 Prophylaxis Oversight Group (POG), for treatments related to prophylaxis.
UK-CTAP and POG meet to consider the advice, briefs and any other information on the treatments. This group then makes a recommendation to CMO England and the principal investigators for each trial.

Prophylaxis Oversight Group (POG) to guide development of pre- and post-exposure prophylaxis for SARS-CoV2 infection.

The POG is formed of a group of independent experts with no vested interests who have the expertise to cover the key issues related to prophylaxis. The group is chaired by Professor David Lalloo.

To advise on national priorities for prophylaxis

* To determine how prophylactic trials fit into the COVID-19 trial landscape
* To support and oversee the prioritisation of prophylaxis agents through the UK CTAP Prophylaxis panel.

POG Board membership
Helen Steel GSK-
VP, Head Shared Safety Sciences and Head Unit Physician Clinical Science (Infectious Diseases) at GLAXOSMITHKLINE R&D

Now……. Any ideas as to who could help with their dilemma? :-)

https://seekingalpha.com/article/4436693-merck-desperate-to-get-back-in-coronavirus-race-with-a-pill

Oh dear, someone left the gate open again at the clown farm.

**this type!

I’m a very accomplished smoker, so fag packet calculations always welcome, particularly these time! Have a good weekend fellow Sareums.

T2, Potnak, thanks for the responses. Makes sense .

Might be a bit of a dumb question this..... the Sareum presentation ref SDC-?1801 states "Manufacturing route completed". As they have always stated their business model is to sell or license the molecules (IP know how etc) , why does the process require them to formulate a manufacturing process?

Really Trimme: as an example:

RE: Share Price18 Jun 2021 12:13
Grow up and read my post properly, I am already in this to my disappointment

Em…..knob jockey and liar?

Catch more bee’s with honey and all that :-)

Trimme, don’t take this the wrong way but could you stop posting pointless excrement. Last week you were incessantly telling the board this was a bum buy, it’s going nowhere et etc. Now (and presumably because you got the entry point you were after) you’ve become a turncoat and are telling all (including the LTH’s) how the market works, and acting like the Sareum master. Personally turncoat equals turd head in my book.

Last one came at 11.19am :-)

Certainly shows on google as 0.7 Euros at present???

Jimton; Of the 13 companies that received grant funding it would appear only 2 others are proposing a potential therapy treatment.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986524/Competition_Results_-_UKRI_Ideas_to_Address_COVID-19_Innovate_UK_de_minimis_Aug_2020.pdf

Jimtom, I have to disagree with your view with regards to covid take a look at the BMJ article below from last month.

Key questions and key answers; Where are we with drug treatments for covid-19? What gaps in treatment remain?

Saye Khoo, professor in the Department of Pharmacology at the University of Liverpool. “We have a moderate pipeline of drugs—we’re not swimming in lots of new candidates and lots of new classes of drugs at the moment,” he says.

Professor Khoo was cited on the original nature article that highlighted TYk2 as a potential treatment. He is also a lead on the Agile program. From my interpretation of the above statement there would not appear to be a great number of promising drugs in the mix.

Sareum was one of only 13 company's to receive grant funding out a total of 244 applications.

Duncan Richards, professor of clinical therapeutics at the University of Oxford, says that this is an important gap to tackle “as we think ahead to next winter when, despite vaccination, we expect there will be significant numbers of patients.”

https://www.bmj.com/content/373/bmj.n1109

Where are we with drug treatments for covid-19?
What gaps in treatment remain?

Saye Khoo, professor in the Department of Pharmacology at the University of Liverpool. “We have a moderate pipeline of drugs—we’re not swimming in lots of new candidates and lots of new classes of drugs at the moment,” he says.

Duncan Richards, professor of clinical therapeutics at the University of Oxford, says that this is an important gap to tackle “as we think ahead to next winter when, despite vaccination, we expect there will be significant numbers of patients.”

https://www.bmj.com/content/373/bmj.n1109

When Tim and co get a minute we can ask them to have a look at Sepsis (Thoth highlighted this many times recently).

Even before the pandemic, about 15 million patients per year presented to US emergency rooms with suspected acute infections or sepsis.

https://www.nature.com/articles/s41586-020-03065-y
https://www.clinicallabmanager.com/thought-leadership/covid-19-and-sepsis-risk-stratifying-patients-based-on-their-immune-response-25187?__hstc=157894565.7fd85d1f04dc3c66b4adc54d97b732af.1624375077710.1624375077710.1624375077710.1&__hssc=157894565.1.1624375077710&__hsfp=1341605859

So…. Wouldn’t want to be out of this by the weekend.

85k at 6p lucky dip for me.

Looks hugely undervalued at present.